How Will The Angina Pectoris Drugs Market Reach $16.42 Billion By 2029 Amid Global Shifts?
Claim 30% Off Global Market Reports With Code ONLINE30 – Insights on Tariff Effects, Global Trade, and Industry Disruptors
#What Is The Projected Valuation Of The Angina Pectoris Drugs Market In The Coming Years?#_x000D_
The market size for drugs treating angina pectoris has been progressively expanding in the past few years. The market is projected to increase from $12.32 billion in 2024 to $12.88 billion in 2025, with a compound annual growth rate (CAGR) of 4.5%. Factors contributing to this increase during the historical period include the widespread occurrence of cardiovascular diseases, an aging populace, lifestyle influences, a rise in hypertension rates, and the prevalence of diabetes._x000D_
_x000D_
In the coming years, it is anticipated that the angina pectoris drugs market will witness robust growth, expanding to a size of $16.42 billion in 2029 with a compound annual growth rate (CAGR) of 6.3%. This predicted surge during the forecast period can be ascribed to increasing worldwide obesity levels, breakthroughs in precision medicine, the emphasis on preventive cardiology, patient information programs, and research into new therapeutic objectives. Foreseeable trends during this period encompass telemedicine for distance monitoring, tangible evidence, and outcome studies, education revolving around patient-centric medication, strategic partnerships for market outreach, advancements in regulations, and fast-tracked approvals._x000D_
_x000D_
#Get A Free Sample Of The Report:#_x000D_
https://www.thebusinessresearchcompany.com/sample.aspx?id=10797&type=smp_x000D_
_x000D_
#Which Demand Drivers Are Strengthening The Angina Pectoris Drugs Market?#_x000D_
The rise in cardiovascular diseases is set to spur the expansion of the angina pectoris drug market. Conditions falling under the umbrella of cardiovascular diseases that affect the heart and blood vessels, such as high blood pressure, coronary artery disease, stroke, and heart failure, are becoming more common. This escalating occurrence of cardiovascular diseases (CVD) can be linked to multiple causes, among them being an aging populace, unhealthy lifestyles, and the widespread issue of obesity. Drugs used to treat angina pectoris such as nitrates, beta-blockers, and calcium channel blockers efficiently alleviate the discomfort and chest pain resulting from reduced blood flow to the heart, invariably boosting the quality of life for the patients. For instance, data released by the British Heart Foundation, a UK-based cardiovascular research charity, in September 2024 indicated that about 7.6 million people in the UK are living with heart and circulatory diseases, amongst which around 4 million are males and 3.6 million are females. These conditions account for approximately 27% of all deaths in the UK, equaling over 170,000 deaths each year, or an average of 480 deaths daily, which amounts to one death every three minutes. As such, the rise in cardiovascular conditions is fuelling the expansion of the angina pectoris drug market._x000D_
_x000D_
#How Does The Angina Pectoris Drugs Market Differ By Segment?#_x000D_
The angina pectoris drugs market covered in this report is segmented – _x000D_
_x000D_
1) By Drugs: Nitrates, Antiplatelet Agents, Beta-adrenergic Blocking Agents, Calcium Channel Blockers, Anti-ischemic Agents, Statins, Antihypertensive Agents, Other Drugs_x000D_
2) By Indication: Stable Angina, Unstable Angina, Prinzmetal’s Angina_x000D_
3) By Route of Administration: Oral, Parenteral, Transdermal, Other Route Of Administrations_x000D_
4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users_x000D_
_x000D_
Subsegments:_x000D_
1) By Nitrates: Short-Acting Nitrates, Long-Acting Nitrates_x000D_
2) By Antiplatelet Agents: Aspirin, Clopidogrel_x000D_
3) By Beta-Adrenergic Blocking Agents: Non-Selective Beta Blockers, Selective Beta Blockers_x000D_
4) By Calcium Channel Blockers: Dihydropyridine Calcium Channel Blockers, Non-dihydropyridine Calcium Channel Blockers_x000D_
5) By Anti-Ischemic Agents: Ranolazine, Ivabradine_x000D_
6) By Statins: Atorvastatin, Rosuvastatin_x000D_
_x000D_
#What New Opportunities Are Emerging From Trends In The Angina Pectoris Drugs Market?#_x000D_
The growth of product innovation is a significant trend being observed in the angina pectoris drugs market. Leading firms in the angina pectoris medications industry are embracing new tech to maintain their market standings. For example, in March 2023, Hikma Pharmaceuticals PLC, a pharmaceutical company based in the UK, initiated the release of Labetalol Hydrochloride Injection, USP, contained in a prefilled syringe. This product has received approval from the United States’ Food and Drug Administration. In medical facilities, the 10 mg/2 mL PFS version is utilized for the treatment of severe hypertension and reduction of high blood pressure._x000D_
_x000D_
#Who Are The Primary Market Leaders In The Angina Pectoris Drugs Market?#_x000D_
Major companies operating in the angina pectoris drugs market include Astellas Pharma Inc., Bayer AG, Novartis AG, AstraZeneca PLC, Bausch Health Companies Inc., Merck & Co Inc., Eli Lilly and Company, Pfizer Inc., Abbott Laboratories, Sun Pharmaceutical Industries Limited, Sanofi SA, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Johnson & Johnson, AERIE PHARMACEUTICALS INC., AbbVie Inc., Amgen Inc., Gilead Sciences Inc., GlaxoSmithKline plc, H. Lundbeck A/S, Ipsen S.A., Lupin Pharmaceuticals Inc., Merck KGaA, Otsuka Pharmaceutical Co. Ltd., Regeneron Pharmaceuticals Inc., Servier Laboratories, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., UCB S.A. _x000D_
_x000D_
#Access The Complete Report Here:#_x000D_
https://www.thebusinessresearchcompany.com/report/angina-pectoris-drugs-global-market-report_x000D_
_x000D_
#Which Region Is Likely To Register The Fastest Growth In The Angina Pectoris Drugs Market?#_x000D_
North America was the largest region in the angina pectoris drugs market in 2024.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the angina pectoris drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa_x000D_
_x000D_
#Customize Your Report Here:#_x000D_
https://www.thebusinessresearchcompany.com/customise?id=10797&type=smp_x000D_
_x000D_
#About The Business Research Company:#_x000D_
_x000D_
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_
_x000D_
#Get in touch with us:#_x000D_
_x000D_
The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_
Americas +1 310-496-7795_x000D_
Asia +44 7882 955267 & +91 8897263534_x000D_
Europe +44 7882 955267_x000D_
Email us at info@tbrc.info_x000D_
_x000D_
#Follow us on:#_x000D_
_x000D_
LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
